Although the positive anti-tumor effects mediated by the VEGFR-inhibitor axitinib seem to outweigh the negative ones, the availability of different VEGFR-inhibitors and the specific knowledge of their distinct immune-modulatory effects requires the careful, attentive choice of each compound depending on the planned treatment plan. Here, KDR is linked to neoplasm.